Q3854: M. R. Deshotels, et al. Angiotensin II Mediates Angiotensin Converting Enzyme Type 2 Internalization and Degradation Through an Angiotensin II Type I Receptor-Dependent Mechanism. Hypertension 2014;64(1368-U438
ALZET Comments: Angiotensin II; leupeptin; Saline; CSF, artificial; SC; CSF/CNS; Mice; 14 days; Controls received mp w/ vehicle; animal info (C57Bl6 or ACE2 KO, 25-30g, 14-16 weeks old); cardiovascular; peptides; bp measured using radiotelemetry; Ang II infused SC; leupeptin infused ICV;

ALZET Comments: Leupeptin; z-VAD-FMK; Ear (cochlea); Guinea pig; 2001; 7 days; Controls received no treatment; animal info (albino, 400-600 g); enzyme inhibitor (caspase); artificial perilymph solution recipe; "A miniature glass pipette with a ring of glue placed next to the tip to provide a leak-proof seal protecting the cochlea from contamination was connected to the catheter." pg 988; tissue perfusion.

ALZET Comments: Leupeptin; E-64a; CSF, artificial; CSF/CNS; Mice (transgenic); 2002; 1 week; Controls received mp w/ vehicle; peptides; ALZET brain infusion kit 3 used; no stress (see pg 22092); neurodegenerative (Alzheimer’s Disease); animal info (male, C57BL/6, APP23 Tg, 8 wks old); lysosomal inhibitor; aCSF recipe.

ALZET Comments: Leupeptin; HEPES, buffer; CSF/CNS; Mice (transgenic); 2004; 2 weeks; Enzyme inhibitor (cysteine protease); cyanoacrylate adhesive; animal info (6 months old, PS/APP, or wt); neurodegenerative (Alzheimer’s Disease); pumps primed in sterile saline at 37 degree Celsius for 48 hours.

ALZET Comments: Leupeptin; PBS; CSF/CNS; Rat; 2002; 14 days; Controls received mp w/ vehicle; enzyme inhibitor (protease); peptides; "The leupeptin infusion rat model is thought to be a useful material for studying several neuronal changes resembling the aging or degeneration of the central nervous tissue." (p. 79).

ALZET Comments: Leupeptin; MDL 28170; Saline, sterile; DMSO; cyclodextrin; CSF/CNS; Rat; 5 days; Controls received mp w/ vehicle; replacement therapy (axotomy); enzyme inhibitor (calpain); 2% DMSO; mp primed overnight at 37 degree Celsius; 10% cyclodextrin used.

ALZET Comments: Leupeptin;; Hank's solution;; ear (round window);; Guinea pig;; 2002;; 8 weeks;; Controls received mp w/ vehicle; tissue perfusion (bulla); long-term study, pumps replaced every 13 days; IntraEAR catheter used; Leupeptin is a potent calpain inhibitor; neuroprotection; buprenorphine given as postoperative analgesic; chloramphenicol given as prophlactic antibiotic;

ALZET®
Bibliography

ALZET Comments: Amyloid protein, beta; Aprotinin; Leupeptin;; HEPES;; CSF/CNS;; Rat; 2004;; 4 weeks; controls received mp w/ vehicle; peptides; ALZET brain infusion kit used; beta-amyloid protein infused alone, or concomitantly with aprotinin or leupeptin; enzyme inhibitors.

ALZET Comments: Leupeptin; CSF, artificial;; CSF/CNS; Rat; 2002; 14 days; controls received mp w/aCSF; ALZET brain infusion kit used.

ALZET Comments: Collagenase inhibitor A; Collagenase inhibitor B; Collagenase inhibitor C; tempol; Superoxide dismutase-PEG; Cytochalasin B; Pepstatin; APMSF; TLCK; SBTI; Leupeptin; E-64; Methylamine; SC; Rat; 2001; 2ML1; 7 days; controls received mp w/vehicle; no stress (see pg. 39); immunology; pumps connected with catheter tubing to 14C-collagen-gelled cotton buds.

ALZET Comments: Leupeptin; IP; mice; 2,5,8,11,14 days; stress/adverse reaction: states IP mp may have had adverse effect on results, however, mp size used was too large for animal/implant site per manufacturer; thiol -protease inhibitor.

ALZET Comments: E-64C; Aprotinin; Chloroquine; Leupeptin; CSF/CNS; Rat; 2002; 2 weeks; no comment posted.

ALZET Comments: Leupeptin; CSF/CNS; gerbil; 3 days; Ischemia (cerebral); peptides.

ALZET Comments: Leupeptin; Saline; IP; Rat; 2 weeks; peptides; thiol protease inhibitor.

ALZET Comments: Leupeptin; Saline; IP; Rat; 2002; 45 days; long-term study, pumps replaced every 15 days; no stress (see pgs. 178, 180).

ALZET Comments: Leupeptin; Saline; CSF/CNS; Rat; 2002; 3 days; controls received mp w/ saline; mp connected to cannula in left ventricle; peptides.

ALZET Comments: Leupeptin; Saline; CSF/CNS; Rat; 10 days; mp model not stated; controls received mp w/saline; peptides; see p.534 for methods.

ALZET Comments: Leupeptin; Saline; CSF/CNS; Rat; 2002; 5 days; controls received mp w/saline; mp connected to catheter in lateral ventricle; 2 experiments were conducted, only 1 used the mp; peptides.
**ALZET Comments:** Arginal, H-D-Phe-Pro-; EP-453; Leupeptin; DMSO; PBS; Propylene glycol; SC; mice; 2001; 5-7 days; controls received mp w/vehicle; mice injected w/melanoma cells; comparison of ip injections vs. mp infusion; cancer; no stress (see p. 4123); peptides.

**ALZET Comments:** Leupeptin; Saline; CSF/CNS; Rat; 2002; 2 weeks; 2 doses leupeptin given; dose-response data; infusion into lateral ventricle; peptides.

**ALZET Comments:** Leupeptin; Aprotinin; Saline; CSF/CNS; Rat; 2002; 2 weeks; comparison of agents effects; 3 different drug concentrations used in mp: 4 mg Leu./ml saline, 8 mg/ml, 20 mg/ml; aprotinin and saline used separately as controls; peptides.

**ALZET Comments:** Chloroquine; Leupeptin; Saline; CSF/CNS; Rat; 2 weeks; mp model not stated; comparison of icv injection vs. mp infusion; comparison of agents effects; 3 doses of leupeptin used; peptides.

**ALZET Comments:** Leupeptin; Saline; SC; Rat; 1 1/2 days; 125I-orosomucoid admin. 12 hours after pump implant; peptides.